- Home
- ARVN vs JBGS Comparison
ARVN vs JBGS Comparison
Compare ARVN & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- JBGS
- Stock Information
- Founded
- ARVN 2015
- JBGS 2016
- Country
- ARVN United States
- JBGS United States
- Employees
- ARVN N/A
- JBGS N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- JBGS Real Estate Investment Trusts
- Sector
- ARVN Health Care
- JBGS Real Estate
- Exchange
- ARVN Nasdaq
- JBGS Nasdaq
- Market Cap
- ARVN 1.7B
- JBGS 1.4B
- IPO Year
- ARVN 2018
- JBGS 2017
- Fundamental
- Price
- ARVN $25.11
- JBGS $15.60
- Analyst Decision
- ARVN Strong Buy
- JBGS Sell
- Analyst Count
- ARVN 13
- JBGS 1
- Target Price
- ARVN $61.08
- JBGS $17.00
- AVG Volume (30 Days)
- ARVN 718.1K
- JBGS 528.2K
- Earning Date
- ARVN 10-30-2024
- JBGS 10-29-2024
- Dividend Yield
- ARVN N/A
- JBGS 4.45%
- EPS Growth
- ARVN N/A
- JBGS N/A
- EPS
- ARVN N/A
- JBGS N/A
- Revenue
- ARVN $161,100,000.00
- JBGS $567,034,000.00
- Revenue This Year
- ARVN $237.44
- JBGS N/A
- Revenue Next Year
- ARVN N/A
- JBGS N/A
- P/E Ratio
- ARVN N/A
- JBGS N/A
- Revenue Growth
- ARVN 1.07
- JBGS N/A
- 52 Week Low
- ARVN $21.17
- JBGS $13.04
- 52 Week High
- ARVN $53.08
- JBGS $18.86
- Technical
- Relative Strength Index (RSI)
- ARVN 48.81
- JBGS 36.10
- Support Level
- ARVN $21.17
- JBGS $14.78
- Resistance Level
- ARVN $28.70
- JBGS $17.58
- Average True Range (ATR)
- ARVN 1.72
- JBGS 0.54
- MACD
- ARVN -0.41
- JBGS -0.13
- Stochastic Oscillator
- ARVN 51.44
- JBGS 26.20
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in and develops real estate assets concentrated in urban infill submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to the legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily and third-party asset management and real estate services. The company generates majority of its revenue from Commercial segment.